

NOVAVAX INC
Form S-8
November 12, 2003

Edgar Filing: NOVAVAX INC - Form S-8

As filed with the Securities and Exchange Commission on November 12, 2003

Registration No. 333- _____

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

22-2816046
(I.R.S. Employer
Identification No.)

8320 Guilford Road, Columbia, Maryland 21046

(Address of Principal Executive Offices) (Zip Code)

1995 STOCK OPTION PLAN

(Full title of the Plan)

Nelson M. Sims
President & Chief Executive Officer
Novavax, Inc.
8320 Guilford Road
Columbia, Maryland 21046
(Name and address of agent for service)

(301) 854-3900

(Telephone number, including area code, of agent for service)

CALCULATION OF REGISTRATION FEE

Title of each class of securities to <u>be registered</u>	Amount to <u>be registered</u>	Proposed maximum offering price <u>per share(1)</u>	Proposed maximum aggregate <u>offering price</u>	Amount of <u>registration</u> <u>fee</u>
Common Stock, \$.01 par value	1,000,000	\$ 6.40	\$ 6,400,000	\$ 517.76

(1) Estimated solely for the purpose of calculating the registration fee, and based upon the average of the high and low prices of the Common Stock on the Nasdaq National Market on November 7, 2003, in accordance with Rules 457(c) and 457(h) of the Securities Act of 1933, as amended.

Edgar Filing: NOVAVAX INC - Form S-8

STATEMENT UNDER GENERAL INSTRUCTION E REGISTRATION OF ADDITIONAL SECURITIES

This Registration Statement is being filed with respect to securities of the same class and issuable under the same employee benefit plan as the securities for which the Registrant filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on December 11, 1995, File No. 33-80279, a Registration Statement on Form S-8, File No. 333-77611, filed on May 3, 1999, a Registration Statement on Form S-8, File No. 333-46000, filed on September 18, 2000, and a Registration Statement on Form S-8, File No. 333-97931, filed on August 9, 2002, the contents of which are incorporated by reference herein.

PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference

The following documents filed by the Registrant with the Securities and Exchange Commission are hereby incorporated by reference in this Registration Statement:

1. The Registrant's Annual Report on Form 10-K for the year ended December 31, 2002;
2. The Registrant's Current Reports on Form 8-K filed on August 8, 2003 and February 25, 2003;
3. The Registrant's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2003, June 30, 2003 and September 30, 2003; and
4. Description of Registrant's Common Stock (\$.01 par value) contained in the Registrant's Registration Statement No. 0-26770 on Form 10 filed on September 14, 1995 pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended.

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all of such securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.

Item 5. Interests of Named Experts and Counsel

Legal matters in connection with the issuance of Common Stock offered hereby have been passed upon for the Registrant by White White & Van Etten LLP, 55 Cambridge Parkway, Cambridge, Massachusetts 02142, as counsel to Registrant. David A. White, a partner of such firm, owns 50,000 shares of the Common Stock of the Registrant.

Item 8. Exhibits

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

Edgar Filing: NOVAVAX INC - Form S-8

/s/ John O. Marsh, Jr. Director November 5, 2003

John O. Marsh, Jr.

/s/ Michael A. McManus Director November 5, 2003

Michael A. McManus

/s/Denis M. O Donnell, M.D. Director and Chairman of the Board November 5, 2003

Denis M. O Donnell, M.D.

Director

Ronald H. Walker

Exhibit Index

<u>Exhibit Number</u>	<u>Description</u>
5	Opinion of White White & Van Etten LLP
10.1	Novavax, Inc. 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.4 to the Company's Registration Statement on Form 10, File No. 0-26770, filed September 14, 1995.)
10.2	First Amendment to Novavax, Inc. 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K, File No. 0-26770, filed April 15, 1999.)
10.3	Second Amendment to Novavax, Inc. 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.3 to the Company's Registration Statement on Form S-8, File No. 333-46000, filed September 18, 2000.)
10.4	Third Amendment to Novavax, Inc. 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.4 to the Company's Registration Statement on Form S-8, File No. 333-97931, filed August 9, 2002.)
10.5	Fourth Amendment to Novavax, Inc. 1995 Stock Option Plan
23.1	Consent of Ernst & Young LLP, independent auditors
23.2	Consent of White White & Van Etten LLP (included in Exhibit 5)
24	Power of Attorney (included in the signature pages of this Registration Statement)